KBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms.
 
Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S. 

KBio

Patrick Doyle

Travis Newton

Oscar Guzmán, M.D. CP

Matt Best

Frank Sutherland

Kurt Wong

The Science and Engineering team at KBio is responsible for the research, development, and optimization of plant-based biologics. This multidisciplinary team focuses on engineering plant systems to produce antibodies and vaccines, developing analytical methods for product characterization, ensuring regulatory compliance, and maintaining process quality and efficiency. Their collaborative efforts drive the innovation and rapid delivery of novel biologic therapies and pandemic response solutions.

Science and Engineering

About

Team members

Other teams at KBio

Leadership Team